- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | -2.97 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2024 (4) | -1.32 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2023 (3) | 0.07 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | -0.73 | 15.12 | -1.39 | -0.80 | 21.57 | 6.98 | -0.73 | 75.42 | -1.39 |
| 25Q4 (7) | -0.86 | -138.89 | -407.14 | -1.02 | -88.89 | -1027.27 | -2.97 | -40.76 | -125.0 |
| 25Q3 (6) | -0.36 | 65.38 | 48.57 | -0.54 | 23.94 | 23.94 | -2.11 | -19.89 | -31.06 |
| 25Q2 (5) | -1.04 | -44.44 | -131.11 | -0.71 | 17.44 | -29.09 | -1.76 | -144.44 | -95.56 |
| 25Q1 (4) | -0.72 | -357.14 | 0.0 | -0.86 | -881.82 | 0.0 | -0.72 | 45.45 | 0.0 |
| 24Q4 (3) | 0.28 | 140.0 | 0.0 | 0.11 | 115.49 | 0.0 | -1.32 | 18.01 | 0.0 |
| 24Q3 (2) | -0.70 | -55.56 | 0.0 | -0.71 | -29.09 | 0.0 | -1.61 | -78.89 | 0.0 |
| 24Q2 (1) | -0.45 | 0.0 | 0.0 | -0.55 | 0.0 | 0.0 | -0.90 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 0.0 | -100.0 | 0.0 | 0.02 | 0.0 | 0.02 | N/A | 本年累計營收成長，主係本年度新增研發用藥收入，致使累計營收較去年同期增加。 | ||
| 2026/3 | 0.02 | 0.0 | 0.0 | 0.02 | 0.0 | 0.02 | 13.39 | 本月營收較去年同期增加，係因本月認列臨床藥物收入所致。 | ||
| 2026/2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.02 | 11.93 | 本公司屬新藥研發公司，本月無營收。 | ||
| 2026/1 | 0.0 | -100.0 | 0.0 | 0.0 | 0.0 | 0.48 | 0.5 | 本公司屬新藥研發公司，本月無營收。 | ||
| 2025/12 | 0.02 | -95.58 | -54.44 | 0.67 | -59.85 | 0.48 | 0.42 | 本月營收較去年同期減少，主係去年同期認列較高銷貨收入；本年累計營收較去年減少，主係去年認列歐洲等區域授權簽約金所致。 | ||
| 2025/11 | 0.46 | 0.0 | 0.0 | 0.65 | -60.0 | 0.46 | 0.44 | 本月營收較去年同期增加，係因本月認列臨床藥物收入；本年累計營收較去年減少，係因去年認列歐洲等區域授權簽約金所致。 | ||
| 2025/10 | 0.0 | 0.0 | -100.0 | 0.2 | -87.94 | 0.0 | 0 | 本月營收較去年同期減少，係因去年同期認列歐洲等區域授權簽約金，致本月營收及累計營收較去年同期減少。 | ||
| 2025/9 | 0.0 | 0.0 | -100.0 | 0.2 | -61.05 | 0.04 | 9.26 | 本月營收較去年同期減少，係因去年同期認列銷貨收入；本年累計營收較去年減少，係因去年累計認列銷貨收入較高所致。。 | ||
| 2025/8 | 0.0 | -100.0 | 0.0 | 0.2 | 104.56 | 0.04 | 9.26 | 累計營收較去年同期增加，係因認列銷貨收入較高所致。 | ||
| 2025/7 | 0.04 | 0.0 | 0.0 | 0.2 | 104.56 | 0.2 | 1.88 | 本月及累計營收較去年同期增加，係因認列銷貨收入較高所致。 | ||
| 2025/6 | 0.0 | -100.0 | 0.0 | 0.16 | 63.02 | 0.16 | 2.1 | 累計營收較去年同期增加，係因認列銷貨收入較高所致。 | ||
| 2025/5 | 0.16 | 0.0 | 64.3 | 0.16 | 63.02 | 0.16 | 2.1 | 本月及累計營收較去年同期增加，係因本月認列銷貨收入較高所致。 | ||
| 2025/4 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.0 | 0 | 本年累計營收較去年減少，係因去年認列銷貨收入。 | ||
| 2025/3 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.0 | 0 | 本年累計營收較去年減少，係因去年認列銷貨收入。 | ||
| 2025/2 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.04 | 7.92 | 本年累計營收較去年減少，係因去年認列銷貨收入。 | ||
| 2025/1 | 0.0 | -100.0 | -100.0 | 0.0 | -100.0 | 0.04 | 7.92 | 本月營收較去年同期減少，係因去年本月認列銷貨收入。 | ||
| 2024/12 | 0.04 | 0.0 | 0.0 | 1.68 | -46.71 | 1.17 | 0.21 | 本月營收較去年同期增加，係因本月認列銷貨收入；本年累計較去年同期減少，係因前期認列授權簽約金收入。 | ||
| 2024/11 | 0.0 | -100.0 | 0.0 | 1.63 | -48.12 | 1.54 | 0.16 | 本年累計較去年同期減少，係因前期認列授權簽約金收入較高所致。 | ||
| 2024/10 | 1.13 | 175.35 | 0.0 | 1.63 | -48.12 | 1.54 | 0.16 | 本月營收較去年同期增加，係因本月認列授權簽約金收入；本年累計較去年同期減少，係因前期認列授權簽約金收入較高所致。 | ||
| 2024/9 | 0.41 | 0.0 | 0.0 | 0.51 | -83.93 | 0.41 | 0.46 | 本月營收較去年同期增加，係因本月認列銷貨收入；本年累計較去年同期減少，係因前期認列授權簽約金收入。 | ||
| 2024/8 | 0.0 | 0.0 | 0.0 | 0.1 | -96.94 | 0.0 | 0 | 去年係因認列授權簽約金收入。 | ||
| 2024/7 | 0.0 | 0.0 | -100.0 | 0.1 | -96.94 | 0.1 | 1.99 | 去年同期係因認列授權簽約金收入。 | ||
| 2024/6 | 0.0 | -100.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥及保健食品 | ||
| 2024/5 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 3.77 | 銷售L606研發用藥 | ||
| 2024/4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
| 2024/3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 銷售保健食品之營收 | ||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |
免責聲明
本網站所有資料僅供參考，如使用者依本資料交易發生交易損失需自行負責，本網站對資料內容錯誤﹑更新延誤不負任何責任。